|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 20, 2024 ) InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CBD API Market Size, Share & Trends Analysis Report By Product (Full Spectrum CBD, Broad Spectrum CBD, CBD Isolate, Water Dispersible CBD Powder), By Origin( Natural, Synthetic), By Indication (Alzheimer's Disease, Autism, Cancer, Chronic Pain, Epilepsy, Migraine, Multiple Sclerosis, Schizophrenia), By End-User (Pharmaceutical Industry, University and Research Institutes) - Market Outlook And Industry Analysis 2031"
Download Free Demo Report: https://www.insightaceanalytic.com/request-sample/1478
Cannabidiol Active Pharmaceutical Ingredient (CBD API) is a highly purified form of CBD that meets stringent standards for pharmaceutical use. As one of the main cannabinoids found in cannabis, CBD is recognized for its potential medicinal properties. Its role as a reliable and consistent ingredient is crucial for researchers and manufacturers developing CBD-based medications. This purity ensures that CBD API maintains uniformity in formulation, making it essential for the precise study and development of therapeutic applications.
CBD API is used in clinical studies to explore its potential therapeutic effects on conditions such as epilepsy, chronic pain, anxiety disorders, and inflammation. Researchers investigate its mechanisms of action and efficacy in controlled settings. Pharmaceutical companies utilize CBD API to formulate medications and treatments. These may include oral capsules, topical creams, and other formulations designed to deliver precise doses of CBD for therapeutic purposes. Ensuring CBD meets pharmaceutical-grade standards is crucial for regulatory approval.
CBD API helps manufacturers adhere to quality control measures, ensuring safety and efficacy in medical products. CBD API is integral to conducting rigorous clinical trials that assess its potential benefits and safety profiles. These trials are essential for gathering evidence to support future medical applications and regulatory approvals.
Growing acceptance of medical cannabis and legalization of CBD in various regions expand the market for CBD API. As more countries legalize medical cannabis or CBD-derived products, demand for pharmaceutical-grade CBD API rises.
List of Prominent Players in the CBD API Market:
• Recipharm
• brains bioceutical
• Purisys
• DSM
• Bedrocan
• CBD API
• Vantage Hemp
• Eurofins
• BIOVECTRA Inc.
• EndoPure
• Biosyyd, UAB
• KD Pharma Group
• Folium Biosciences
• Kinetochem
• Colombian Golden
• Averix Bio, LLC
• Veranova
• KND Labs
• Jordan Process
• GVB Biopharma
Market Dynamics:
Drivers-
Growing consumer preference for natural and plant-based remedies fuels demand for CBD API. The trend towards holistic health and wellness products further supports its market growth. Increasing investments in research and development by pharmaceutical companies and academic institutions propel innovation in CBD-based medications. This research focus drives market expansion by exploring new therapeutic uses and formulations. CBD API's versatility in formulations supports its application in various medical products, including oils, capsules, and topical solutions. This diversification broadens its market appeal across different therapeutic areas. Increasing awareness and research into the potential health benefits of CBD drive demand. Studies indicating its efficacy in treating conditions such as epilepsy, anxiety, and chronic pain contribute to its market growth.
Challenges:
Dependence on complex global supply chains for sourcing raw materials, such as hemp, and ensuring consistent supply amid regulatory changes and geopolitical factors can pose logistical challenges.
Regional Trends:
North America leads the market. The regional market growth is due to the legalization of hemp-derived CBD under the Farm Bill. Growing consumer demand for CBD products, including pharmaceutical-grade CBD API. The legalization of both medical and recreational cannabis has fostered a robust market for CBD products, supporting research and development in pharmaceutical applications. However, Asia Pacific is expected to be the fastest-growing region. Legalization of medical cannabis and increasing acceptance of CBD products drive market growth, with emphasis on pharmaceutical-grade standards.
Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/1478
Recent Developments:
• In June 2024, DSM Firmenich, the cannabinoid market with the introduction of CBtru®, the first-ever intermediate CBD medicinal product. The intermediate is an improved version of the CBD active pharmaceutical ingredient (API), which is what gives the medication its effectiveness. It is prepared for further development into a final product. Oral solid dose forms can be produced because of CBtru®'s superior characteristics.
• In July 2024, GB Sciences, signs a letter of intent with Endopure Life Sciences to get a license to develop and commercialize their cannabis-based Parkinson's formulation.
• In April 2023, DSM Firmenich, has announced a new strategic partnership to investigate the therapeutic potential of CBD-based oral dispersible tablets for the treatment of insomnia. Oz Medicann Group (OMG) Pharma is an Australian biotech developer in the cannabis medicines arena.
Segmentation of CBD API Market-
By Product,
• Full spectrum CBD
• Broad-spectrum CBD
• CBD isolate
• Water Dispersible CBD Powder
• Others
By Origin,
• Natural
• Synthetic
By Indication,
• Alzheimer's Disease
• Autism
• Cancer
• Chronic Pain
• Epilepsy
• Migraine
• Multiple Sclerosis
• Schizophrenia
• Others
By End-User
• Pharmaceutical Industry
• University and Research Institutes
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
For More Customization @ https://www.insightaceanalytic.com/customisation/1478
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Insight Ace Analytics
Diana D’souza
+8884144123
diana.dsouza@insightaceanalytics.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
